Proteostasis impairment in protein-misfolding and -aggregation diseases

Trends in Cell Biology

Volumn 24, Issue 9, 2014, Pages 506-514

  Hipp, Mark S ^a,b   Park, Sae Hun ^a,b   Hartl, Ulrich ^a,b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

Degradation; Molecular chaperones; Neurodegenerative disease; Protein (mis)folding; Protein aggregation; Proteostasis

Indexed keywords

PROTEOME; CHAPERONE; PROTEIN;

AGING; CELL DEATH; COLLAPSE; DISEASES; FUNCTIONAL STATUS; HUMAN; INTERVENTION STUDY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN MISFOLDING; REVIEW; GENETICS; HOMEOSTASIS; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; PROTEINOSIS; PROTEOSTASIS DEFICIENCY;

AGING; HOMEOSTASIS; HUMANS; MOLECULAR CHAPERONES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING; PROTEINS; PROTEOLYSIS; PROTEOSTASIS DEFICIENCIES;

EID: 84906794886     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.05.003     Document Type: Review

References (117)

1. Balch W.E., et al. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
2. Powers E.T., et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 2009, 78:959-991.
3. Kim Y.E., et al. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem. 2013, 82:323-355.
4. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10(Suppl.):S10-S17.
5. Ciryam P., et al. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 2013, 5:781-790.
6. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
7. Ellis R.J., Minton A.P. Protein aggregation in crowded environments. Biol. Chem. 2006, 387:485-497.
8. Dunker A.K., et al. Function and structure of inherently disordered proteins. Curr. Opin. Struct. Biol. 2008, 18:756-764.
9. Haslbeck M., et al. Some like it hot: the structure and function of small heat-shock proteins. Nat. Struct. Mol. Biol. 2005, 12:842-846.
10. Kampinga H.H., Craig E.A. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat. Rev. Mol. Cell Biol. 2010, 11:579-592.
11. Tyedmers J., et al. Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 2010, 11:777-788.
12. Taipale M., et al. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11:515-528.
13. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
14. Varshavsky A. The ubiquitin system, an immense realm. Annu. Rev. Biochem. 2012, 81:167-176.
15. Smith M.H., et al. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 2011, 334:1086-1090.
16. Araki K., Nagata K. Protein folding and quality control in the ER. Cold Spring Harb. Perspect. Biol. 2011, 3:a007526.
17. Kettern N., et al. Chaperone-assisted degradation: multiple paths to destruction. Biol. Chem. 2010, 391:481-489.
18. Prakash S., Matouschek A. Protein unfolding in the cell. Trends Biochem. Sci. 2004, 29:593-600.
19. Escusa-Toret S., et al. Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress. Nat. Cell Biol. 2013, 15:1231-1243.
20. Spokoini R., et al. Confinement to organelle-associated inclusion structures mediates asymmetric inheritance of aggregated protein in budding yeast. Cell Rep. 2012, 2:738-747.
21. Kundu M., Thompson C.B. Autophagy: basic principles and relevance to disease. Annu. Rev. Pathol. 2008, 3:427-455.
22. Arndt V., et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. Curr. Biol. 2010, 20:143-148.
23. Gamerdinger M., et al. BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins. EMBO Rep. 2011, 12:149-156.
24. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000, 10:524-530.
25. Kaganovich D., et al. Misfolded proteins partition between two distinct quality control compartments. Nature 2008, 454:1088-1095.
26. Specht S., et al. Hsp42 is required for sequestration of protein aggregates into deposition sites in Saccharomyces cerevisiae. J. Cell Biol. 2011, 195:617-629.
27. Johnston J.A., et al. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 1998, 143:1883-1898.
28. Iwata A., et al. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 2005, 280:40282-40292.
29. Sontag E.M., et al. Sorting out the trash: the spatial nature of eukaryotic protein quality control. Curr. Opin. Cell Biol. 2014, 26:139-146.
30. Dice J.F. Chaperone-mediated autophagy. Autophagy 2007, 3:295-299.
31. Morley J.F., et al. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10417-10422.
32. David D.C., et al. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol. 2010, 8:e1000450.
33. Ben-Zvi A., et al. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14914-14919.
34. Kirkwood T.B. Evolution of ageing. Nature 1977, 270:301-304.
35. Vilchez D., et al. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 2012, 489:304-308.
36. Carnemolla A., et al. Contesting the dogma of an age-related heat shock response impairment: implications for cardiac-specific age-related disorders. Hum. Mol. Genet. 2014, 10.1158/1535-7163.MCT-11-0174.
37. Demontis F., Perrimon N. FOXO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. Cell 2010, 143:813-825.
38. Liu B., et al. The polarisome is required for segregation and retrograde transport of protein aggregates. Cell 2010, 140:257-267.
39. Rujano M.A., et al. Polarised asymmetric inheritance of accumulated protein damage in higher eukaryotes. PLoS Biol. 2006, 4:e417.
40. Douglas P.M., Dillin A. Protein homeostasis and aging in neurodegeneration. J. Cell Biol. 2010, 190:719-729.
41. Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
42. Cohen E., et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139:1157-1169.
43. Gupta R., et al. Firefly luciferase mutants as sensors of proteome stress. Nat. Methods 2011, 8:879-884.
44. Park S.H., et al. PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. Cell 2013, 154:134-145.
45. Gidalevitz T., et al. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006, 311:1471-1474.
46. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
47. Miller J., et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 2011, 7:925-934.
48. Olzscha H., et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 2011, 144:67-78.
49. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
50. Blake M.J., et al. Concomitant decline in heat-induced hyperthermia and HSP70 mRNA expression in aged rats. Am. J. Physiol. 1991, 260:R663-R667.
51. Bersuker K., et al. Heat shock response activation exacerbates inclusion body formation in a cellular model of Huntington disease. J. Biol. Chem. 2013, 288:23633-23638.
52. Hay D.G., et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 2004, 13:1389-1405.
53. Yamanaka T., et al. Mutant huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J. 2008, 27:827-839.
54. Anckar J., Sistonen L. Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu. Rev. Biochem. 2011, 80:1089-1115.
55. Raychaudhuri S., et al. Interplay of acetyltransferase EP300 and the proteasome system in regulating heat shock transcription factor 1. Cell 2014, 156:975-985.
56. Lowe J., et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. 1988, 155:9-15.
57. Waelter S., et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 2001, 12:1393-1407.
58. Tonoki A., et al. Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process. Mol. Cell. Biol. 2009, 29:1095-1106.
59. López-Otín C., et al. The hallmarks of aging. Cell 2013, 153:1194-1217.
60. Bennett E.J., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
61. Hipp M.S., et al. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J. Cell Biol. 2012, 196:573-587.
62. Kristiansen M., et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 2007, 26:175-188.
63. Urushitani M., et al. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 2002, 83:1030-1042.
64. Illing M.E., et al. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 2002, 277:34150-34160.
65. Venkatraman P., et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 2004, 14:95-104.
66. Deriziotis P., et al. Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J. 2011, 30:3065-3077.
67. Bennett E.J., et al. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 2005, 17:351-365.
68. Juenemann K., et al. Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes. J. Biol. Chem. 2013, 288:27068-27084.
69. Hageman J., et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol. Cell 2010, 37:355-369.
70. Summers D.W., et al. The type II Hsp40 Sis1 cooperates with Hsp70 and the E3 ligase Ubr1 to promote degradation of terminally misfolded cytosolic protein. PLoS ONE 2013, 8:e52099.
71. Prasad R., et al. A nucleus-based quality control mechanism for cytosolic proteins. Mol. Biol. Cell 2010, 21:2117-2127.
72. Chai Y., et al. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 1999, 19:10338-10347.
73. Wang J., et al. Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1392-1397.
74. Yu A., et al. Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1481-E1490.
75. Broadley S.A., Hartl F.U. The role of molecular chaperones in human misfolding diseases. FEBS Lett. 2009, 583:2647-2653.
76. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
77. Leroy E., et al. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
78. Winklhofer K.F. Parkin and mitochondrial quality control: toward assembling the puzzle. Trends Cell Biol. 2014, 24:332-341.
79. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14:248-264.
80. Anttonen A-K., et al. The gene disrupted in Marinesco-Sjögren syndrome encodes SIL1, an HSPA5 cochaperone. Nat. Genet. 2005, 37:1309-1311.
81. Senderek J., et al. Mutations in SIL1 cause Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract and myopathy. Nat. Genet. 2005, 37:1312-1314.
82. Hansen J.J., et al. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am. J. Hum. Genet. 2002, 70:1328-1332.
83. Magen D., et al. Mitochondrial Hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am. J. Hum. Genet. 2008, 83:30-42.
84. Taylor R.C., Dillin A. XBP-1 is a cell-nonautonomous regulator of stress resistance and longevity. Cell 2013, 153:1435-1447.
85. van Oosten-Hawle P., et al. Regulation of organismal proteostasis by transcellular chaperone signaling. Cell 2013, 153:1366-1378.
86. Kern A., et al. HSF1-controlled and age-associated chaperone capacity in neurons and muscle cells of C. elegans. PLoS ONE 2010, 5:e8568.
87. Tsvetkov A.S., et al. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat. Chem. Biol. 2013, 9:586-592.
88. Schaffar G., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 2004, 15:95-105.
89. Auluck P.K., et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
90. Sittler A., et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 2001, 10:1307-1315.
91. Ozcan U., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
92. Mu T.W., et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008, 134:769-781.
93. Casas-Tinto S., et al. The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum. Mol. Genet. 2011, 20:2144-2160.
94. Tsaytler P., et al. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 2011, 332:91-94.
95. Sarkar S., et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 2009, 16:46-56.
96. Lee B.H., et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467:179-184.
97. Gidalevitz T., et al. The stress of protein misfolding: from single cells to multicellular organisms. Cold Spring Harb. Perspect. Biol. 2011, 3:a009704.
98. Labbadia J., et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 2011, 121:3306-3319.
99. Sidrauski C., et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife 2013, 2:e00498.
100. Leitman J., et al. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat. Commun. 2013, 4:2753.
101. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
102. Scherzinger E., et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4604-4609.
103. Gusella J.F., MacDonald M.E. Huntington's disease: seeing the pathogenic process through a genetic lens. Trends Biochem. Sci. 2006, 31:533-540.
104. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
105. Yamamoto A., et al. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
106. Shirasaki D.I., et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron 2012, 75:41-57.
107. Hartl F.U., et al. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475:324-332.
108. Vabulas R.M., Hartl F.U. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science 2005, 310:1960-1963.
109. Duttler S., et al. Principles of cotranslational ubiquitination and quality control at the ribosome. Mol. Cell 2013, 50:379-393.
110. Rock K.L., et al. Re-examining class-I presentation and the DRiP hypothesis. Trends Immunol. 2014, 35:144-152.
111. Wojcik C., DeMartino G.N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 2003, 35:579-589.
112. Rosenbaum J.C., et al. Disorder targets misorder in nuclear quality control degradation: a disordered ubiquitin ligase directly recognizes its misfolded substrates. Mol. Cell 2011, 41:93-106.
113. Iwata A., et al. Intranuclear degradation of polyglutamine aggregates by the ubiquitin-proteasome system. J. Biol. Chem. 2009, 284:9796-9803.
114. Kose S., et al. Hikeshi, a nuclear import carrier for Hsp70s, protects cells from heat shock-induced nuclear damage. Cell 2012, 149:578-589.
115. Heck J.W., et al. Cytoplasmic protein quality control degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1106-1111.
116. Guerriero C.J., et al. Hsp70 targets a cytoplasmic quality control substrate to the San1p ubiquitin ligase. J. Biol. Chem. 2013, 288:18506-18520.
117. Rousseau E., et al. Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones. J. Biol. Chem. 2009, 284:1917-1929.